Abstract: The present invention refers to the construction of cloning vectors containing the max gene. Especially, the present invention refers to the introduction of cloning vectors containing the max gene in cells using transport vectors. In addition, the presence of cloning vectors containing the max gene in cells allows the differential expression of the max gene in the same cells. In addition, the present invention refers to a method of gene therapy in which the differential expression of the max gene has cytoprotective activity, especially neuroprotective activity, and is capable of application to medical and veterinary therapeutics of neurodegenerative conditions.

Abstract: The invention relates to stable crystal modifications of (R,S)-, (R)- and (5S)-DOPC, to a process for the preparation of these modifications, and to the use thereof as constituent for the preparation of medicaments.

Abstract: Described are stable compressed pharmaceutical dosage forms, such as tablets, layered so that incompatible active ingredients can be included in a single dosage form, and such that carry-over and intermixing are minimized in the manufacture process.

Abstract: The method for increasing lactose tolerance in subjects exhibiting lactose intolerance symptoms implements a protocol where the subjects ingest a gradually increasing amount of lactose containing product over a six week period. At various points during the six week period the subject ingests the lactose containing product once a day and then twice a day. The lactose containing product can be in liquid form, such as for example, milk, and is preferably in a powder form which is taken either by ingesting capsules having the lactose powder or in a granular form mixed with water or other non-lactose containing liquid.

Abstract: The invention relates to a capsule for the prevention of cardiovascular diseases which comprises coated tablets of acetylsalicylic acid, coated tablets of simvastatin or pravastatin, and coated tablets of lisinopril, ramiphl or perindopril. The capsules are used for the prevention of cardiovascular diseases in high-risk populations.

Abstract: Polymers and compositions, collectively “bioadhesive materials”, with improved bioadhesive properties have been developed. One or more compounds comprising: a) an aromatic moiety comprising two or more hydroxyl substituents, methoxy substituents, substituents hydrolyzable to hydroxyl substituents, or a combination thereof, and b) a primary or secondary amino moiety are either covalently attached to a polymer or are physically mixed with a polymer to form a bioadhesive material. These bioadhesive materials can be used, for example, to fabricate new drug delivery or diagnostic systems with increased residence time at tissue surfaces, and consequently increase the bioavailability of a drug or a diagnostic agent.

Abstract: The subject invention provides a pharmaceutical tablet formulation comprising per unit dosage form e.g.

Abstract: The present invention relates to a new manufacture process for producing an iron containing phosphate adsorbent, in particular to a process for manufacturing and isolating an iron(III)-based phosphate adsorbent which exhibits valuable pharmacological properties.

Abstract: The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms.

Abstract: The invention describes a new class of crystalline silica material having two levels of porosity and structural order. At the first level, building units are nanoslabs of uniform size having zeolite framework. At the second structural level, nanoslabs are assembled, e.g. linked through their corners, edges or faces following patterns imposed by interaction with cationic surfactant or triblock copolymer molecules. After evacuation of these molecules, microporosity is obtained inside the nanoslabs, and a precise mesoporosity between the nanoslabs depending on the tiling pattern of the zeolite nanoslabs, as evidenced by X-ray diffraction. These materials are useful for the fixation of biologically active species, such as poorly soluble drugs.

Abstract: A polyethylene glycol (PEG) aerogel particles having an average particle diameter not substantially above about 2?, a volumetric porosity of greater than about 50%, and pore sizes capable of retaining drug molecules. A method for preparing such polyethylene glycol (PEG) aerogel particles includes initiating a catalyzed reaction using a catalyst of PEG forming ingredients to form PEG particles; partially drying the formed PEG particles under conditions to control pore size; and subjecting the partially dried formed PEG particles to CO2 supercritical extraction for form the PEG aerogel particles. Drug molecules include chemotherapeutic agents. The surface of the PEG aerogel particles are reactable with a variety of agents, for example, to selectively target tumors, protects irreversible damage to labile proteins, and protects degradation of sensitive drugs with subsequent loss of biological efficacy.

Abstract: The present invention provides antibiofilm composition comprising two or more agents selected from the group consisting of DispersinB™, 5-Fluorouracil, Deoxyribonuclease I and Proteinase K for preventing growth and proliferation of biofilm-embedded microorganisms in wound care, oral care, and disease-related infections and methods of treatment in mammals. The invention further provides methods for preparing medical devices, and wound care devices using an antibiofilm composition comprising two or more antimicrobial agents selected from the group consisting of DispersinB™, 5-Fluorouracil, Deoxyribonuclease I and Proteinase K.

Abstract: The present invention provides delayed release pharmaceutical compositions comprising an active pharmaceutical ingredient, e.g. mycophenolate sodium, and an enteric polymer, and methods for preparing the same. Preferably, the pharmaceutical compositions do not contain a coating.

Abstract: Provided herein is a novel raantlelate sail of fesoterodine, process for the preparation, pharmaceutics!! compositions, and method of treating thereof. Provided also herein are solid state forms of fesoterodine mandelate, process for the preparation, pharmaceutical compositions, and method of treating thereof. The raandelate salt of fesoterodine is useful for preparing fesoterodine free base or a pharmaceutically acceptable salt thereof; particularly fesoterodine fumaraie, in high purity.

Abstract: Methods for preparing microparticles having reduced residual solvent levels. Microparticles are contacted with a non-aqueous washing system to reduce the level of residual solvent in the microparticles. Preferred non-aqueous washing systems include 100% ethanol and a blend of ethanol and heptane. A solvent blend of a hardening solvent and a washing solvent can be used to harden and wash microparticles in a single step, thereby eliminating the need for a post-hardening wash step.

Abstract: Described herein are methods for identifying novel nucleic acid regulatory elements and compounds that modulate the regulation of such elements. Also described herein are nucleic acid sequence identified as novel nucleic acid regulatory elements and host cells containing such nucleic acid regulatory elements in a vector.

Abstract: Provided is a simple and easy method of producing an innoxious dry earthworm powder, while suppressing inactivation of the enzymes contained in earthworms. In the method, a homogenate obtained by grinding living earthworms is freeze-dried and the dried product is heat-treated at a temperature of 110° C. or higher but lower than 130° C. Preferably, the method according to the present invention comprises further a process for preparation of the living earthworms, which precedes the grinding step, comprising the steps of: standing the living earthworms under light for 10 to 50 hours; removing the dirt formed on the skin thereof, bringing the earthworms into contact with an organic acid for 30 seconds or less; diluting the acid with addition of water to adjust the pH of the aqueous acidic solution to a pH in the range of 2 to 5; standing the earthworm mixture under the pH condition for 3 to 180 minutes; and then washing the earthworms with water.

Abstract: The invention relates to the use of argon gas for producing all or part of an inhalable medicinal product intended to prevent or treat a neurointoxication in humans. The medicinal product contains argon in an effective proportion and acts on at least one brain receptor in order to regulate the functioning of dopamine-, glutamate-, serotonin-, acetylcholine-, taurine-, GABA- and/or noradrenalin-mediated neurotransmission systems. Preferably, the proportion by volume of argon in the gaseous medicinal product is between 15 and 80%. The neurointoxication is chosen from excitotoxicities engendering a state of addiction, acute cerebral accidents, neurodegenerative diseases, and psychiatric or neurological pathologies, in particular anxiety conditions, psychotic conditions, in particular schizophrenia, and epilepsy in its various forms.

Abstract: This invention involves the formulation of stable powders which, when dissolved in water form a non-pressurized carbonated solution supersaturated with calcium and phosphate ions, and also containing the presence of carbon dioxide and sodium bicarbonate. The resulting solution is used as an oral rinse for the prevention and treatment of inflammatory processes of the soft tissues of the mouth, throat and oral cavity, which may result from infection or trauma to the oral mucosal tissue.

Abstract: A low ether gel composition for application to skin comprising a keratolytic agent, in particular salicylic acid, and comprising a nitrocellulose and one or more volatile ingredients, which forms a film on contact with skin adequate to form a protective barrier for the keratolytic agent for a period of time necessary to provide treatment to the skin; methods of treating using such compositions, and dispensers containing such compositions.

Abstract: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase the solubility and air stability of the resulting 17-ammonium hydroquinone ansamycin analog.

Abstract: The present invention relates to compositions for the treatment of cancerous tissues in warm-blooded animals containing one or two anticancer agents attached to polymeric carriers having monomer units derived from one or more of N-(2-carboxypropyl)methacrylamide (2-CPMA), N-(3-carboxypropyl)methacrylamide (3-CPMA), N-(2-aminopropyl)methacrylamide (2-APMA) and/or N-(3-aminopropyl)methacrylamide (3-APMA) are also included. Anticancer agents in compositions can be attached to said polymeric carrier by side-chains which can be susceptible to hydrolysis by lysosomal enzymes intracellularly. Compositions can also include a targeting ligand attached to the polymeric carrier, optionally through a second linker.

Abstract: The present invention relates to pharmaceutical formulations comprising the protein kinase inhibitor, MP470, and methods of using same in treating conditions involving undesirable cell proliferation, such as cancer.

Abstract: The invention relates to the use of one or more cannabinoids, particularly THC and/or CBD in combination with a non-cannabinoid chemotherapeutic agent in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM). The non-cannabinoid chemotherapeutic agent may be a selective estrogen receptor modulator or an alkylating agent.

Abstract: A nasal spray solution for use as a nasal spray and methods of using the solution are disclosed. The nasal spray solution moisturizes nasal passages and alleviates nasal dryness. The solution includes a hypotonic saline solution, wherein the saline solution is hypotonic with respect to cells of the nasal mucosa of the nasal passages, a buffering agent, a lubricating agent, and an anti-microbial agent.

Abstract: A vegetal-derived, water-absorbing composition comprising (i) a vegetal cholesterol derived semi-synthetically from one or a mixture of botanical materials from Dioscorea composita, Dioscorea terpinapensis, Dioscorea villosa and/or Trillium erectum, (ii) a non-animal, botanically-derived phospholipid comprising at least 20% phosphatidylcholine, (iii) a botanical oil or ester derivative at a concentration of from 50% to 90% by weight, based on the total weight of the water-absorbing composition, (iv) at least one sucrose ester at a concentration of from 5% to 10% by weight, based on the total weight of the water-absorbing composition, and (v) fumed silica at a concentration of 8% to 15% by weight, based on the total weight of the water-absorbing composition. The vegetal-derived, water-absorbing composition is capable of absorbing between 200% and 400% of its weight of water and may be used as a substitute for lanolin.

Abstract: Disclosed are compositions and corresponding methods of their use that include extracts from Loropetalum chinensis, Camptotheca acuminate, Lonicera maackii, Washingtonia filifera, Artemisia parviflora, Glochidion lanceolaris, Polygonum hydropiper, Populus davidiana, Tsoongiodendron odorum, Trema angustifolia, Ficus tikoua, Pistacia chinensis, Zizyphus mauritiana, Garuga forrestii, Michelia figo, Sabina chinensis, Cuphea balsamona, Setaria palmifolia, Polygonum lapathifolium, Machilus longipedicellata, Geranium nepalense, Ipomoea obscura, Cedrus deodara, Quercus aliena, Carqueja, Condurango, Catuaba, Carex baccans, Chrysalidocarpus lutescens, Gnaphalium pensylvanicum, Celtis sinensis, Cassia siamea, Catalpa yunnanesis, Potamogenton perforliatus, Cinnamomum japonicum, or any combination thereof.

Abstract: An aqueous antiseptic composition for eliminating microorganisms that cause Bovine mastitis in dairy animals is disclosed. The composition comprises about 10 to 50% by volume of lemongrass oil and at least one solubilizing agent for solubilizing the lemongrass oil. The composition also comprises about 10 to 30% by volume of a carrier oil carrying the components of the composition and about 0.5 to 2% by volume of an electrolyte for providing conductivity for the composition. The composition further comprises an organic acid for adjusting the pH level of the composition and an antioxidant.

Abstract: Disclosed are a composition for the prophylaxis of influenza viral infection comprising a sumac extract, an air filter coated with the same, and an air cleaner comprising the air filter. Having high inhibitory activity against influenza virus, the composition comprising a sumac extract can be applied to the prevention of influenza viral infection. Also, the filter coated with the composition can remove influenza viruses from the air so that it can be employed in an air cleaner for the prophylaxis of influenza viral infection.

Abstract: A composition including (a) a Platelet Activating Factor (PAF) Inhibitor and (b) an antioxidant which interferes with the arachidonic acid cascade and also has antioxidant activity. The composition is useful for the treatment or the relief of inflammatory diseases, thrombosis, cardiac problems, and/or conditions caused by platelet induced blood clotting.

Abstract: An extrusion head configured for at least one extruder includes a flow channel a finishing die; and an opening in operative communication with the flow channel, wherein the opening is configured to at least partially accommodate a screw shaft of an additional extruder.

Abstract: Disclosed is a safety connector for a hot runner having a valve stem and an actuation plate, the safety connector including: (i) a latch releasably interlocking the valve stem with the actuation plate so that in response to movement of the actuation plate, the valve stem becomes movable; and (ii) a latch mover being cooperative with the latch, and the latch mover being configured to move the latch responsive to a predetermined force acting on the valve stem so that so that the valve stem is released from the actuation plate.

Abstract: A detachable punch mold includes a mold base, a clamp member, a punch, and a fastening member for securing the clamp member and the punch to the mold base. The clamp member defines a slot therein. The punch is partially engaged in the slot of the clamp member and partially protruding out from the clamp member. Both of the clamp member and the punch are detachably attached to the mold base.

Abstract: The method and the device are used for mounting forms of a heating process of tires that are produced from an elastomeric material. Form segments of the form are held detachably by a support device. Mounting pins of a guiding element supporting the form segments, said pins being provided with a mounting profile, are guided through an insertion recess of a fixation element disposed in the region of the support device. Thereafter, a locking element of the fixation element is positioned transversely to the longitudinal direction of the mounting pin and thereby locked by the mounting profile with respect to the fixation element. Before carrying out the transversal positioning of the locking element, a tensioning element, which adjusts the fixation element in a longitudinal direction of the mounting pin, is displaced against a spring force. Thereafter, the tensioning element is reset by the spring force in order to hold the mounting profile of the mounting pin in the region of the fixation element by positive fit.

Abstract: A crossover nozzle system for transferring molten plastic from an inlet at the center of the stationary platen of an injection machine to the main manifold of the molding chambers of the stack molds of the injection molding machine. The crossover nozzle system incorporates liquid cooling to create a high viscosity viscous seal from molten plastic at a parting line between moveable components. Accordingly, no other seal is required between the components.

Abstract: An injection drive apparatus for injection molding machines is revealed. Liquid material is fed into a mold smoothly by a material feeding screw of a material feeding mechanism. Then a reaction force is generated to push the material feeding screw when the material feeding hole is nearly full of the material. Thus the material feeding screw and the slide mechanism assembled therewith are pushed to move backward. Later the injection mechanism is driven by the slide mechanism to move and act on the drive screw. Thus the slide mechanism threaded with the drive screw is driven to push the material feeding screw moving forward and squeezing the material for injection molding. Therefore, the load of the motor is reduced dramatically and the yield rate of the products produced by injection molding is increased due to the two-stage action-feeding of the material and squeezing of the material for injection.

Abstract: This invention relates to the selection and use of nonpathogenic, lysine-uptake stimulating lactic acid bacteria strains, and products and methods using such strains for example for improvement of fur-coat and claws quality in pet-animals.

Abstract: A method is described for improving the nutritional value of a foodstuff comprising a source of myo-inositol hexakisphosphate by feeding the foodstuff in combination with a phytase expressed in yeast. The method comprises the step of feeding the animal the foodstuff in combination with a phytase expressed in yeast wherein the phytase can be selected from the group consisting of AppA1, AppA2 and a site-directed mutant of AppA. The invention also enables reduction of the feed to weight gain ratio and an increase bone mass and mineral content of an animal. A foodstuff and a feed additive comprising AppA2 or a site-directed mutant of AppA are also described.

Abstract: Method for incorporating polyunsaturated fatty acids into milk with improved efficiency. The methods include protecting the polyunsaturated fatty acids, including omega-3 and omega-6 polyunsaturated fatty acids, with a protective agent prior to feeding the fatty acids to a milk producing animal. Methods for feeding polyunsaturated fatty acids to milk producing animals by top dressing a polyunsaturated fatty acid supplement on top of animal feed compositions and methods of making and using such compositions are also provided.

Abstract: A method for modifying poultry products with beneficial fatty acids comprising feeding a fowl with a standard feed in which the animal or vegetable oil blend component of the feed is replaced by, or supplemented with, an oil blend consisting of at least 50% fish oil, canola oil (10-30%), soy oil and/or soap stock (0-40%) and linseed oil (0-30%), at total oil levels added to the feed from about 2.5% up to about 7.0%, calculated based on the final feed composition. The modified poultry products obtained maintain the natural smell and taste. Also described are chicken eggs, chicken meat and turkey meat having increased content of monounsaturated fatty acids and reduced content of saturated fatty acids.

Abstract: A food product of non-uniform shape may be manufactured from an edible composition such as starch by introducing said composition to an extruder having a barrel and subjecting the composition to shear and heat to form a melt, and conveying the melt through an adjustable orifice while varying the cross-section dimensions of the orifice to form an extrudate having thickness dimensions that varies along its length. This may be followed by cutting the extrudate to length. The extrudate may also be passed between cooperating cavities and formed to shape. The extrudate may also be guided into predetermined patterns by repositioning the die relative to a molding surface.

Abstract: The invention encompasses the use of a lipolytic enzyme obtainable from one of the following genera: Streptomyces, Corynebacterium and Thermobifida in various methods and uses, wherein the lipolytic enzyme hydrolyzes a glycolipid or a phospholipid or transfers an acyl group from a glycolipid or phospholipids to an acyl acceptor. The present invention also relates to a lipolytic enzyme that hydrolyzes at least a galactolipid or transfers an acyl group from a galactolipid to one or more acyl acceptor substrates, wherein the enzyme is obtainable from Corynebacterium species.

Abstract: A transgenic plant cell expressing a maltogenic amylase (such as Novamyl®) or a beta-amylase; a transgenic plant regenerated from said cell; seeds generated from such plant where said seeds comprise a maltogenic amylase or a beta-amylase and the use of said seeds, optionally in ground form, for catalyzing an industrial process, such as e.g. in baking. The maltogenic amylase providing an anti staling effect in bread produced from the seeds in question.

Abstract: The invention relates to the use of one or more pectinolytic enzyme(s) for the treatment of fruit or vegetable mash as well as a process for enzymatic treatment of fruit or vegetable mash comprising the step of adding one or more pectinolytic enzyme(s), wherein at least one pectinolytic enzyme is obtainable from Trichoderma reesei, as well as to a process for the preparation of a fruit or vegetable juice comprising the process for enzymatic treatment of fruit or vegetable mash. Moreover, the invention discloses recombinant DNA molecules encoding a polypeptide having endo-polygalacturonase activity, a polypeptide having exo-polygalacturonase activity, a polypeptide having exo-rhamnogalacturonase activity and a polypeptide having xylogalacturonase activity.

Abstract: Provided is an enzymatic process that hydrolyzes spinach plant material to form a salt-enhancing ingredient, the formed salt-enhancing ingredient, food products comprising said salt-enhancing ingredient and a method of enhancing the salty taste of food products.

Abstract: A fortified liquid composition, comprising purified water, molecular oxygen at a level between 30 and 60 mg/l, and a combination of minerals in that purified water. The minerals include at least 0.002 mg/l boron, at least 0.0001 mg/I chromium, at least 0.045 mg/l cobalt, at least 0.019 mg/I copper, at least 0.086 mg/l iodine, at least 0.053 mg/l manganese, at least 0.36 mg/l potassium, at least 0.0003 mg/I selenium, at least 0.029 mg/l silica, at least 2.61 mg/l sodium, and at least 0.015 mg/l zinc.

Abstract: The present invention refers to a nutrient supplement composition and its use in the production of wine. The nutrient supplement composition comprises methionine and biotin for use in the alcoholic fermentation of an organic substrate, in particular for use in the alcoholic fermentation of grape juice mediated by Saccharomyces cerevisiae. The invention further refers to a use of methionine and biotin as nutrient supplements, to a method for supplementation of nutrients, and to a procedure of fermentation.

Abstract: The present embodiments generally relate to beverages with enhanced flavors and aromas and method of making same. Some embodiments of the present disclosure are directed to soluble coffee and methods of making soluble coffee with improvements in such qualities as taste and aroma.

Abstract: Disclosed are bitter alkaloid-containing consumables comprising bitter blockers for a reduced alkaloid-derived bitterness and methods of forming said consumables.

Abstract: A granular blend comprising a sweetener fortified with vitamins A, C, D, E, and K. The sweetener may comprise white or brown natural sugar, artificial sweetener, or a mixture of the two. The vitamins may optionally include vitamins B6 and B12, and iron. The granular blend may be provided in packaged form enclosed in an envelope.